全文获取类型
收费全文 | 9977篇 |
免费 | 684篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 70篇 |
儿科学 | 356篇 |
妇产科学 | 182篇 |
基础医学 | 1441篇 |
口腔科学 | 191篇 |
临床医学 | 1571篇 |
内科学 | 1834篇 |
皮肤病学 | 142篇 |
神经病学 | 1000篇 |
特种医学 | 154篇 |
外科学 | 847篇 |
综合类 | 101篇 |
一般理论 | 19篇 |
预防医学 | 1348篇 |
眼科学 | 107篇 |
药学 | 690篇 |
中国医学 | 35篇 |
肿瘤学 | 593篇 |
出版年
2023年 | 77篇 |
2022年 | 105篇 |
2021年 | 215篇 |
2020年 | 149篇 |
2019年 | 208篇 |
2018年 | 265篇 |
2017年 | 197篇 |
2016年 | 199篇 |
2015年 | 231篇 |
2014年 | 341篇 |
2013年 | 511篇 |
2012年 | 661篇 |
2011年 | 808篇 |
2010年 | 462篇 |
2009年 | 366篇 |
2008年 | 721篇 |
2007年 | 709篇 |
2006年 | 706篇 |
2005年 | 674篇 |
2004年 | 623篇 |
2003年 | 526篇 |
2002年 | 531篇 |
2001年 | 84篇 |
2000年 | 58篇 |
1999年 | 94篇 |
1998年 | 130篇 |
1997年 | 85篇 |
1996年 | 82篇 |
1995年 | 66篇 |
1994年 | 66篇 |
1993年 | 64篇 |
1992年 | 59篇 |
1991年 | 50篇 |
1990年 | 41篇 |
1989年 | 46篇 |
1988年 | 28篇 |
1987年 | 29篇 |
1986年 | 21篇 |
1985年 | 25篇 |
1984年 | 23篇 |
1983年 | 29篇 |
1982年 | 40篇 |
1981年 | 44篇 |
1980年 | 34篇 |
1979年 | 27篇 |
1978年 | 36篇 |
1977年 | 18篇 |
1975年 | 17篇 |
1973年 | 12篇 |
1972年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
Erin Tutty Chriselle Hickerton Bronwyn Terrill Belinda McClaren Rigan Tytherleigh Elaine Stackpoole Jaqueline Savard Ainsley Newson Anna Middleton Amy Nisselle Marie Cusack Melissa Adamski Clara Gaff Sylvia Metcalfe 《Health expectations》2021,24(2):670
BackgroundConsumer genomic testing for nutrition and wellness, (nutritional genomics), is becoming increasingly popular. Concurrently, health‐care practitioners (HPs) working in private practice (including doctors interested in integrative medicine, private genetic counsellors, pharmacists, dieticians, naturopaths and nutritionists) are involved as test facilitators or interpreters.ObjectiveTo explore Australian consumers’ and HPs’ experiences with nutrigenomic testing.MethodSemi‐structured in‐depth interviews were conducted using predominantly purposive sampling. The two data sets were analysed individually, then combined, using a constant comparative, thematic approach.ResultsOverall, 45 interviews were conducted with consumers (n = 18) and HPs (n = 27). Many of the consumer interviewees experienced chronic ill‐health. Nutrigenomic testing was perceived as empowering and a source of hope for answers. While most made changes to their diet/supplements post‐test, self‐reported health improvements were small. A positive relationship with their HP appeared to minimize disappointment. HPs’ adoption and views of nutrigenomic testing varied. Those enthusiastic about testing saw the possibilities it could offer. However, many felt nutrigenomic testing was not the only ‘tool’ to utilize when offering health care.DiscussionThis research highlights the important role HPs play in consumers’ experiences of nutrigenomics. The varied practice suggests relevant HPs require upskilling in this area to at least support their patients/clients, even if nutrigenomic testing is not part of their practice.Patient or public contributionAdvisory group included patient/public group representatives who informed study design; focus group participants gave feedback on the survey from which consumer interviewees were sourced. This informed the HP data set design. Interviewees from HP data set assisted with snowball sampling. 相似文献
73.
74.
Connie A. Haley Patricia Macias Supriya Jasuja Betsy A. Jones Marie-Claire Rowlinson Roshni Jaimon Pennelyn Onderko Elaine Darnall Maria E. Gomez Charles Peloquin David Ashkin Neela D. Goswami 《Emerging infectious diseases》2021,27(1):332
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose. 相似文献
75.
76.
77.
Neves Lia Mara Grosso Tim Carla Roberta Floriano Elaine Medeiros da Silva de Avó Lucimar Retto Fernandes João Batista Parizotto Nivaldo Antonio Cominetti Marcia Regina 《Lasers in medical science》2021,36(4):863-870
Lasers in Medical Science - Ultraviolet radiation (UVR) is the major etiologic agent of cutaneous photoaging, and different strategies are used to prevent and treat this condition. The... 相似文献
78.
Kristin M D'Silva Sara Jane Cromer Elaine W Yu Michael Fischer Seoyoung C Kim 《Journal of bone and mineral research》2021,36(1):52-60
Zoledronic acid (ZA) is an effective agent in osteoporosis and malignancy-related bone disease but may be associated with increased risk of atrial fibrillation (AF), although current studies disagree on this risk. To examine the risk of incident AF among patients receiving ZA compared with denosumab in the first year of treatment, we performed a new-user, active comparator cohort study including privately insured Americans between January 1, 2010, and June 30, 2019. Individuals aged ≥50 years without known arrhythmia or advanced kidney disease who initiated ZA were 1:1 propensity score (PS)-matched to individuals initiating denosumab in separate osteoporosis and malignancy cohorts. The primary outcome was incident diagnosis of AF (≥ 1 inpatient or ≥ 2 outpatient diagnostic codes) over 1 year. Secondary outcomes included stroke/transient ischemic attack (TIA) and nonvertebral fracture. In the osteoporosis cohort (n = 16,235 pairs), mean age was 71 years, and 93% were female. There was higher risk of AF with ZA compared with denosumab over 1 year (incidence rate [IR] = 18.6 versus 14.9 per 1000 person-years; hazard ratio [HR] = 1.25; 95% confidence interval [CI] 1.04 to 1.50). In the malignancy cohort (n = 7732 pairs), mean age was 70 years, and 66% were female. There was a numerically higher, albeit not statistically significant, risk of AF with ZA compared with denosumab over 1 year (IR = 46.9 versus 39.0 per 1000 person-years; HR = 1.19; 95% CI 1.00 to 1.43; p = 0.06). No difference in stroke/TIA rates occurred. In the malignancy cohort, ZA was less effective than denosumab at preventing nonvertebral fractures (HR = 1.32; 95% CI 1.01 to 1.74). Compared with denosumab, ZA treatment for osteoporosis and possibly for malignancy-related bone disease is associated with modestly increased risk of incident AF in the first year of treatment. © 2020 American Society for Bone and Mineral Research (ASBMR). 相似文献
79.
Ryan Schutt Jamie Case Sunil M. Kurian Samantha R. Spierling Bagsic Bethany L. Barrick Alice E. Toll Qiuheng Zhang Elaine F. Reed Michael M. Quigley Randolph Schaffer Jonathan S. Fisher James C. Rice Christopher L. Marsh 《Transplantation proceedings》2021,53(3):950-961
Although interest in the role of donor-specific antibodies (DSAs) in kidney transplant rejection, graft survival, and histopathological outcomes is increasing, their impact on steroid avoidance or minimization in renal transplant populations is poorly understood. Primary outcomes of graft survival, rejection, and histopathological findings were assessed in 188 patients who received transplants between 2012 and 2015 at the Scripps Center for Organ Transplantation, which follows a steroid avoidance protocol. Analyses were performed using data from the United Network for Organ Sharing. Cohorts included kidney transplant recipients with de novo DSAs (dnDSAs; n = 27), preformed DSAs (pfDSAs; n = 15), and no DSAs (nDSAs; n = 146). Median time to dnDSA development (classes I and II) was shorter (102 days) than in previous studies. Rejection of any type was associated with DSAs to class I HLA (P < .05) and class II HLA (P < .01) but not with graft loss. Although mean fluorescence intensity (MFI) independently showed no association with rejection, an MFI >5000 showed a trend toward more antibody-mediated rejection (P < .06), though graft loss was not independently associated. Banff chronic allograft nephropathy scores and a modified chronic injury score were increased in the dnDSA cohort at 6 months, but not at 2 years (P < .001 and P < .08, respectively). Our data suggest that dnDSAs and pfDSAs impact short-term rejection rates but do not negatively impact graft survival or histopathological outcomes at 2 years. Periodic protocol post-transplant DSA monitoring may preemptively identify patients who develop dnDSAs who are at a higher risk for rejection. 相似文献
80.
Elaine Ku Charles E. McCulloch Deborah B. Adey Libo Li Kirsten L. Johansen 《Journal of the American Society of Nephrology : JASN》2021,32(3):677
BackgroundPatients may accrue wait time for kidney transplantation when their eGFR is ≤20 ml/min. However, Black patients have faster progression of their kidney disease compared with White patients, which may lead to disparities in accruable time on the kidney transplant waitlist before dialysis initiation.MethodsWe compared differences in accruable wait time and transplant preparation by CKD-EPI estimating equations in Chronic Renal Insufficiency Cohort participants, on the basis of estimates of kidney function by creatinine (eGFRcr), cystatin C (eGFRcys), or both (eGFRcr-cys). We used Weibull accelerated failure time models to determine the association between race (non-Hispanic Black or non-Hispanic White) and time to ESKD from an eGFR of ≤20 ml/min per 1.73 m2. We then estimated how much higher the eGFR threshold for waitlisting would be required to achieve equity in accruable preemptive wait time for the two groups.ResultsBy eGFRcr, 444 CRIC participants were eligible for waitlist registration, but the potential time between eGFR ≤20 ml/min per 1.73 m2 and ESKD was 32% shorter for Blacks versus Whites. By eGFRcys, 435 participants were eligible, and Blacks had 35% shorter potential wait time compared with Whites. By the eGFRcr-cys equation, 461 participants were eligible, and Blacks had a 31% shorter potential wait time than Whites. We estimated that registering Blacks on the waitlist as early as an eGFR of 24–25 ml/min per 1.73 m2 might improve racial equity in accruable wait time before ESKD onset.ConclusionsPolicies allowing for waitlist registration at higher GFR levels for Black patients compared with White patients could theoretically attenuate disparities in accruable wait time and improve racial equity in transplant access. 相似文献